Publication:
High-frequency optical coherence tomography predictors of aneurysm occlusion following flow diverter treatment in a preclinical model

dc.contributor.coauthorKing, Robert M.
dc.contributor.coauthorAnagnostakou, Vania
dc.contributor.coauthorRaskett, Christopher M.
dc.contributor.coauthorArends, Jennifer M.
dc.contributor.coauthorDixit, Harish G.
dc.contributor.coauthorUghi, Giovanni J.
dc.contributor.coauthorPuri, Ajit S.
dc.contributor.coauthorGounis, Matthew J.
dc.contributor.coauthorShazeeb, Mohammed Salman
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorPeker, Ahmet
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2025-01-19T10:33:41Z
dc.date.issued2023
dc.description.abstractBackground High-frequency optical coherence tomography (HF-OCT) is an intravascular imaging method that allows for volumetric imaging of flow diverters in vivo. Objective To examine the hypothesis that a threshold for both volume and area of communicating malapposition can be predictive of early aneurysm occlusion. Methods Fifty-two rabbits underwent elastase aneurysm formation, followed by treatment with a flow diverter. At the time of implant, HF-OCT was acquired to study the rate and degree of communicating malapposition. Treated aneurysms were allowed to heal for either 90 or 180 days and euthanized following catheter angiography. Healing was dichotomized into aneurysm remnant or neck remnant/complete occlusion. Communicating malapposition was measured by HF-OCT using a semi-automatic algorithm able to detect any points where the flow diverter was more than 50 μm from the vessel wall. This was then summed across image slices to either a volume or area. Finally, a subsampled population was used to train a statistical classifier for the larger dataset. Results No difference in occlusion rate was found between device type or follow-up time (p=0.28 and p=0.67, respectively). Both volume and area of malapposition were significantly lower in aneurysms with a good outcome (p<0.001, both). From the statistical model, a volume of less than 0.56 mm 3 or a normalized area less than 0.69 as quantified by HF-OCT was predictive of occlusion (p<0.001, each). Conclusions HF-OCT allows for measurements of both volume and area of malapposition and, from these measurements, an accurate prediction for early aneurysm occlusion can be made. © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue9
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipFunding text 1: ASP: consultant for Medtronic Neurovascular, Stryker Neurovascular, Balt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc, and Arsenal Medical; research grants from NIH, Microvention, Cerenovus, Medtronic Neurovascular, and Stryker Neurovascular; holds stocks in InNeuroCo, Agile, Perfuze, Galaxy and NTI. JMA and HGD are employees of Stryker Neurovascular. GJU is an employee of Gentuity. MJG: has been a consultant on a fee-per-hour basis for Alembic LLC, Astrocyte Pharmaceuticals, BendIt Technologies, Cerenovus, Imperative Care, Jacob’s Institute, Medtronic Neurovascular, Mivi Neurosciences, phenox GMbH, Q’Apel, Route 92 Medical, Scientia, Stryker Neurovascular, Stryker Sustainability Solutions, Wallaby Medical; holds stock in Imperative Care, InNeuroCo, Galaxy Therapeutics and Neurogami; and has received research support from the National Institutes of Health (NIH), the United States – Israel Binational Science Foundation, Agile, Anaconda, ApicBio, Arsenal Medical, Axovant, Balt, Cerenovus, Ceretrieve, CereVasc LLC, Cook Medical, Galaxy Therapeutics, Gentuity, Gilbert Foundation, Imperative Care, InNeuroCo, Insera, Jacob’s Institute, Magneto, MicroBot, Microvention, Medtronic Neurovascular, MIVI Neurosciences, Naglreiter MDDO, Neurogami, Philips Healthcare, Progressive Medical, Pulse Medical, Rapid Medical, Route 92 Medical, Scientia, Stryker Neurovascular, Syntheon, ThrombX Medical, Wallaby Medical, the Wyss Institute and Xtract Medical. MJG is associate editor of Basic Science on the JNIS editorial board. MSS: has been a consultant on a fee-per-hour basis for Sanofi; and has research support from Sio Gene Therapies, Inozyme, the National Institutes of Health (NIH), Gilbert Foundation, and Massachusetts Life Science Center. ; Funding text 2: This study was sponsored by Stryker Neurovascular and a Bits-2-Bytes grant from the Massachusetts Life Sciences Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.
dc.description.volume15
dc.identifier.doi10.1136/jnis-2022-019275
dc.identifier.eissn1759-8486
dc.identifier.issn17598478
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85141389387
dc.identifier.urihttps://doi.org/10.1136/jnis-2022-019275
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26656
dc.identifier.wos844721400001
dc.keywordsAneurysm
dc.keywordsDevice
dc.keywordsFlow Diverter
dc.keywordsIntervention
dc.keywordsTechnology
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.relation.grantnoAstrocyte Pharmaceuticals; BendIt Technologies; CereVasc LLC; Gilbert Foundation; Sio Gene Therapies; Stryker Neurovascular; National Institutes of Health, NIH; United States - Israel Binational Science Foundation, BSF; Massachusetts Life Sciences Center, MLSC; Kenora and Lake of the Woods Community Foundation, NTI
dc.relation.ispartofJournal of Neurointerventional Surgery
dc.subjectMedicine
dc.titleHigh-frequency optical coherence tomography predictors of aneurysm occlusion following flow diverter treatment in a preclinical model
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorPeker, Ahmet
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files